Recent Updates
Recently added Catalysts

PEDIACEL and Prevenar

Phase 3

Diphtheria | Monoclonal antibody | Infectious Disease |Sanofi|Last Updated: Jun 3, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment588

FDA Designations

No designations recorded

Clinical trial landscape

PEDIACEL and Prevenar · 1 trial · 5 indications

Phase 3 1
NCT00343421Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and ToddlersDiphtheria
COMPLETED588 Analytics
PHASE3COMPLETED
Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers
DiphtheriaUnlock trial analytics

Study Endpoints

Primary Endpoints

To provide information concerning the immunogenicity of PEDIACEL® and Infanrix®-IPV+Hib
1 month post-vaccination

Secondary Endpoints

To provide information concerning the safety after administration of PEDIACEL® and Infanrix®-IPV+Hib
Entire study
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Group 1EXPERIMENTALPEDIACEL co-administered with Prevenar
Group 2ACTIVE_COMPARATORInfanrix-IPV+Hib co-administered with Prevenar

Interventions

NameTypeDescription
PEDIACEL® and Prevenar®BIOLOGICAL0.5 mL each, IM (opposite thigh)
Infanrix®-IPV+Hib and Prevenar®BIOLOGICAL0.5 mL each, IM (opposite thigh)
Unlock Study Design Details

Eligibility Criteria

Age Range55 Days to 75 Days
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Infants 55 to 75 days old, inclusive on the day of first vaccination * Born at full term of pregnancy (\> 37 weeks) * Informed consent form signed by the parent(s) or the legal guardian * Parents or the legal guardian able to read and write in the local language * Parent(s) or...

Countries:FrancePoland
Unlock Eligibility Criteria

Frequently asked questions about PEDIACEL and Prevenar

What is PEDIACEL and Prevenar used for?

PEDIACEL and Prevenar are investigational vaccines studied for the prevention of diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. They are being developed by Sanofi (SNY) for use in infants and toddlers, with a focus on infectious disease prevention.

Who makes PEDIACEL and Prevenar?

Sanofi (SNY) is developing PEDIACEL and Prevenar. These are investigational vaccines studied in a Phase 3 clinical trial for the prevention of multiple infectious diseases, including diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

What phase is PEDIACEL and Prevenar in?

PEDIACEL and Prevenar are in Phase 3 clinical development. They are investigational vaccines and have not been approved for use. A Phase 3 trial has been completed to evaluate their safety and immunogenicity when co-administered in infants and toddlers.

What clinical trials is PEDIACEL and Prevenar in?

PEDIACEL and Prevenar have one completed Phase 3 clinical trial, NCT00343421, which enrolled 588 participants in France and Poland. The study compared Pediacel to Infanrix-IPV+Hib when both were co-administered with Prevenar in infants and toddlers.

How does PEDIACEL and Prevenar work?

PEDIACEL and Prevenar are vaccines designed to stimulate the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. They are administered to infants and toddlers to help prevent these infectious diseases.